The cost of care of systemic lupus erythematosus (SLE) in the UK: Annual direct costs for adult SLE patients with active autoantibody-positive disease

Lupus

Volumn 23, Issue 3, 2014, Pages 273-283

  Khamashta, M A ^a   Bruce, I N ^b,c   Gordon, C ^d,e   Isenberg, D A ^f   Ateka Barrutia, O ^a   Gayed, M ^d,e   Donatti, C ^g   Guillermin, A L ^g   Foo, J ^h   Perna, A ^h  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g IQVIA   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

antinuclear antibody; direct cost; health care resources; Lupus flare; management costs

Indexed keywords

ANTINUCLEAR ANTIBODY; DIRECT COST; HEALTH CARE RESOURCES; LUPUS FLARE; MANAGEMENT COSTS;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; COST CONTROL; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MULTIVARIATE ANALYSIS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PREVALENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATE MEDICINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894092979     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313517407     Document Type: Article

References (30)

1. Balluz L, Philen R, Ortega L, et al. Investigation of systemic lupus erythematosus in Nogales, Arizona. Am J Epidemiol. 2001 ; 154: 1029-1036
2. Govoni M, Castellino G, Bosi S, Napoli N, Trotta F. Incidence and prevalence of systemic lupus erythematosus in a district of north Italy. Lupus. 2006 ; 15: 110-113
3. López P, Mozo L, Gutiérrez C, Suárez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: Gender and age influence on immunological features. Lupus. 2003 ; 12: 860-865
4. Nightingale AL, Farmer RD, de Vries CS. Systemic lupus erythematosus prevalence in the UK: Methodological issues when using the General Practice Research Database to estimate frequency of chronic relapsing-remitting disease. Pharmacoepidemiol Drug Saf. 2007 ; 16: 144-151
5. Piette JC, Papo T, Amoura Z and Godeau P. Lupus érythé mateux systémique. In: Godeau P, Herson S and Piette J-C (eds), Traité de médecine. Quatriéme ed. Paris: Flammarion Médecine-Sciences, 2004; 142-148.
6. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum. 1995 ; 38: 551-558
7. Panopalis P, Clarke AE. Systemic lupus erythematosus: Clinical manifestations, treatment and economics. Expert Rev Pharmacoecon Outcomes Res. 2006 ; 6: 563-575
8. Clarke AE, Panopalis P, Petri M, et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford). 2008 ; 47: 329-333
9. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006 ; 65: 1175-1183
10. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol. 2009 ; 5: 400-404
11. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2001 ; 40: 37-47
12. Wilson EC, Jayne DR, Dellow E, Fordham RJ. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology (Oxford). 2007 ; 46: 1096-1101
13. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum. 2009 ; 61: 1159-1167
14. Doria A, Amoura Z, Cervera R, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis. Epub ahead of print 21 December 2012.
15. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999 ; 10: 413-424
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
17. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
18. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988 ; 31: 817-825
19. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000 ; 27: 373-376
20. National Schedule of Reference Costs Year: '2009-10 - NHS Trusts and PCTs combined. Department of Health 2011, http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH-123459-(accessed 25 April 2011).
21. British National Formulary No. 61. BNF 2011, http://bnf.org/bnf/ (accessed 25 April 2011).
22. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med. 2005 ; 142 (12 Pt 1): 953-962
23. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999 ; 8: 685-691
24. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 ; 353: 2550-2558
25. Slawsky KA, Fernandes AW, Fusfeld L, Manzi S, Goss TF. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken). 2011 ; 63: 1224-1232
26. Zhu TY, Tam LS, Li EK. Cost-of-illness studies in systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken). 2011 ; 63: 751-760
27. Clarke AE, Petri MA, Manzi S, et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol. 1999 ; 26: 1500-1511
28. Clarke AE, Penrod J, St Pierre Y, et al. Underestimating the value of women: Assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol. 2000 ; 27: 2597-2604
29. Clarke AE, Petri M, Manzi S, et al. The systemic lupus erythematosus Tri-nation Study: Absence of a link between health resource use and health outcome. Rheumatology (Oxford). 2004 ; 43: 1016-1024
30. Bexelius C, Wachtmeister K, Skare P, Jönsson L, Vollenhoven Rv. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): A Swedish nationwide study based on patient reports. Lupus. 2013 ; 22: 793-801